Andrew Sandham, executive chairman, Syntaxin

pharmafile | October 20, 2009 | Appointment | Research and Development |  appointment, appointments, research and development, syntaxin 

Syntaxin, a biopharmaceutical company developing novel biologic drugs that control cell secretion, has appointed Andrew Sandham executive chairman.

This follows the resignation of chief exeuctive, Patrick Doyle, for personal reasons.  Mr Sandham has worked closely with Syntaxin since its formation in 2005, as chairman of the board.  A search has been initiated for the vacant chief executive position.